GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Common Stock

BCAL Diagnostics (ASX:BDX) Common Stock : A$22.80 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics Common Stock?

BCAL Diagnostics's quarterly common stock increased from Dec. 2022 (A$19.23 Mil) to Jun. 2023 (A$19.28 Mil) and increased from Jun. 2023 (A$19.28 Mil) to Dec. 2023 (A$22.80 Mil).

BCAL Diagnostics's annual common stock increased from . 20 (A$0.00 Mil) to Jun. 2022 (A$18.87 Mil) and increased from Jun. 2022 (A$18.87 Mil) to Jun. 2023 (A$19.28 Mil).

BCAL Diagnostics Common Stock Historical Data

The historical data trend for BCAL Diagnostics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics Common Stock Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23
Common Stock
18.87 19.28

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Common Stock Get a 7-Day Free Trial 18.84 18.87 19.23 19.28 22.80

BCAL Diagnostics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

BCAL Diagnostics (ASX:BDX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Common Stock
Comparable Companies
ASX:GTG ASX:CTE ASX:LDX ASX:IBX ASX:RHY ASX:IIQ ASX:GSS ASX:MAP TMO DHR SHSE:603259 IQV IDXX A XSWX:LONN MTD ICLR LH ILMN DGX
Traded in Other Exchanges
N/A
Address
Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230
Website
https://www.bcaldiagnostics.com
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.